MP52-18 PRETREATMENT TESTOSTERONE LEVEL IS THE PREDICTIVE FACTOR ASSOCIATED WITH METABOLIC SYNDROME IN PATIENTS OF PROSTATE CANCER AFTER ANDROGEN DEPRIVATION THERAPY | Zendy

AI Assistant Blog Pricing

MP52-18 PRETREATMENT TESTOSTERONE LEVEL IS THE PREDICTIVE FACTOR ASSOCIATED WITH METABOLIC SYNDROME IN PATIENTS OF PROSTATE CANCER AFTER ANDROGEN DEPRIVATION THERAPY

Details

The content you want is available to Zendy users.Already have an account? Click here. to sign in.